Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hisanori Hara

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Biopharmaceutics & Drug Disposition|September 2, 2018
CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisibStefan De Buck, Klaus Kucher, Hisanori Hara, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 3, 2014
Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled studyAnton Drollmann, Romain Sechaud, Parasar Pal, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 27, 2014
Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteersAnton Drollmann, Matthew Brown, Romain Sechaud, et al.
Rapid Communications in Mass Spectrometry : RCM|February 18, 2004
Simultaneous analytical method for the determination of TCH346 and its four metabolites in human plasma by liquid chromatography/tandem mass spectrometryHisanori Hara, Takashi Uchimura, Naotsugu Akashi, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 28, 2012
Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting beta2-agonist, in different ethnic populationsSoichiro Matsushima, Ivan Matthews, Ralph Woessner, et al.
Clinical Pharmacology in Drug Development|April 26, 2018
Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy SubjectsOlivier J David, Rhett Behrje, Parasar Pal, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy VolunteersSoniya S Vaidya, Sanjeev Khindri, Suzanne Maahs, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 10, 2007
Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometryNozomu Koseki, Hiroto Kawashita, Hisanori Hara, et al.
European Journal of Drug Metabolism and Pharmacokinetics|October 3, 2015
Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese SubjectsRomain Sechaud, Surendra Machineni, Hanns-Christian Tillmann, et al.
Pulmonary Pharmacology & Therapeutics|February 5, 2016
Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjectsSoniya S Vaidya, Sanjeev Khindri, Nicole Calder, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Biopharmaceutics & Drug Disposition|September 2, 2018
CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisibStefan De Buck, Klaus Kucher, Hisanori Hara, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 3, 2014
Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled studyAnton Drollmann, Romain Sechaud, Parasar Pal, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 27, 2014
Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteersAnton Drollmann, Matthew Brown, Romain Sechaud, et al.
Rapid Communications in Mass Spectrometry : RCM|February 18, 2004
Simultaneous analytical method for the determination of TCH346 and its four metabolites in human plasma by liquid chromatography/tandem mass spectrometryHisanori Hara, Takashi Uchimura, Naotsugu Akashi, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 28, 2012
Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting beta2-agonist, in different ethnic populationsSoichiro Matsushima, Ivan Matthews, Ralph Woessner, et al.
Clinical Pharmacology in Drug Development|April 26, 2018
Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy SubjectsOlivier J David, Rhett Behrje, Parasar Pal, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy VolunteersSoniya S Vaidya, Sanjeev Khindri, Suzanne Maahs, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 10, 2007
Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometryNozomu Koseki, Hiroto Kawashita, Hisanori Hara, et al.
European Journal of Drug Metabolism and Pharmacokinetics|October 3, 2015
Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese SubjectsRomain Sechaud, Surendra Machineni, Hanns-Christian Tillmann, et al.
Pulmonary Pharmacology & Therapeutics|February 5, 2016
Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjectsSoniya S Vaidya, Sanjeev Khindri, Nicole Calder, et al.
Pageof 2